NEW YORK, August 10, 2026, 07:02 EDT
- The stock hovered around $4.30 ahead of Monday’s market open, nearly twice Friday’s closing price.
- Following the acquisition, the number of shares rose to 78.43 million, nearly tenfold compared to March.
- Trading volume before the market opened was more than five times the size of the company’s reported free float.
Jin Medical International Ltd. NASDAQ:ZJYL surged by almost 100% in premarket trade on Monday. The stock traded at $4.3425, representing a 101.98% gain as of 6:59 a.m. EDT. Nasdaq’s regular trading session begins at 9:30 a.m. EDT.
The headline rise conceals a broader reset in valuation. Jin Medical reported 78.43 million shares outstanding following its July acquisition. Based on the premarket price, this equates to roughly $340.6 million in equity value.
Some quote pages continued to show a market capitalisation close to $16.8 million, calculated from Friday’s $2.15 closing price and the previous 7.83 million-share count. This is roughly a tenth of the value reported in filings.
Liquidity could account for the pace. As of July 28, just 1.673 million Class A shares were non-restricted. Premarket volume reached 9.07 million, which is 5.4 times greater than the available float.
The increase developed over Friday’s close, extended in after-hours trade, and continued into Monday’s premarket.
| Trading point | Price | Change versus prior regular close | Reported volume |
|---|---|---|---|
| Friday regular session close | $2.1500 | +11.98% | 6.33M |
| Friday after the bell | $4.2299 | +96.74% | 6.14M |
| Monday premarket, 06:59 EDT | $4.3425 | +101.98% | 9.07M |
The stock advanced 11.4% during last week’s regular sessions, rising from Monday’s $1.93 close to finish at $2.15 on Friday, after hitting a low of $1.53 on Thursday. The majority of the price movement occurred in the latter part of the week.
The operating environment showed mixed trends. Unaudited revenue for the first half declined, but gross margin saw an improvement. The company posted a minor net loss.
| Six months ended March 31 | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Revenue | $8.9M | $9.9M | Down 9.7% |
| Gross profit | $2.4M | $2.4M | Little changed |
| Gross margin | 26.9% | 24.3% | Up 2.6 points |
| Research and development | $0.9M | $0.7M | Rose 33.4% |
| Net income or loss | $(0.2)M | $0.01M | Turned to loss |
Chief Executive Erqi Wang pointed to “temporary foreign-exchange pressure” linked to the top Japanese client. He noted $30.1 million in cash and investments underpinning a “solid financial position.” PR Newswire
Wheelchair revenue declined by 1.4% to $7.1 million. Sales of components increased 9.9% to $1.1 million. Other-product revenue dropped 59.1% after electric-scooter sales ended due to failed qualifications.
The shift in capital structure was more pronounced. Jin Medical issued 64.19 million shares for the acquisition and 6.42 million shares for advisers. Combined, these account for 90.0% of the total after the deal.
| Capital measure | March 31 | July 28 or transaction amount | Investor read-through |
|---|---|---|---|
| Total shares outstanding | 7.827M | 78.432M | Up 902%; nearly 10 times higher |
| Acquisition consideration shares | — | 64.186M | Represents 81.8% of shares after transaction |
| Adviser consideration shares | — | 6.419M | Equals 8.2% of post-transaction shares |
| Non-restricted Class A shares | — | 1.673M | 2.13% of aggregate shares |
The post-transaction tally at Friday’s close indicated an equity value of $168.6 million. At a share price of $4.3425, the value calculated was $340.6 million. These amounts are based on reporter estimates, not company figures.
The purchase price was set at $1.641 per share. The 6:59 quote on Monday was 164.6% higher than this offer price. This gap highlights how the outdated market-cap number is even less relevant.
The movement is not backed by an established sell-side consensus. MarketWatch, using data from FactSet, showed no available recommendations, ratings, or price targets.
| Analyst recommendation metric | Latest value |
|---|---|
| Mean recommendation | N/A |
| Total ratings | N/A |
| Consensus target price | N/A |
| Buy, hold, sell distribution | N/A |
The initial focus for the week is on Monday’s standard market open. Investors are monitoring for signs of broader participation outside the narrow non-restricted group. Another key question is whether the price holds up amid fuller regular-session liquidity.
Risks stay heightened. Limited free-floating supply could cause swift reversals in gains. The Tongsheng deal employs VIE agreements instead of holding shares outright. A single group of customers accounted for 73.3% of revenue in the first half, and each Class B share holds 800 votes.
Related articles: Stock Market
